基线PLA2R1表位扩展预测膜性肾病缓解率降低
该前瞻性队列纳入58例PLA2R1抗体阳性的原发性膜性肾病患者,随机分配至利妥昔单抗组或仅抗蛋白尿治疗组。基线表位扩展与PLA2R1抗体滴度强相关,且独立于年龄、性别、基线抗体水平和治疗分组,与第6个月及末次随访时缓解率降低相关。
要点
- 基线存在PLA2R1表位扩展提示原发性膜性肾病缓解可能性降低。
- 表位扩展与PLA2R1抗体滴度强相关,但与年龄、性别、蛋白尿等无关。
- 利妥昔单抗治疗可使部分患者第6个月表位扩展逆转。
核心结论
- 基线PLA2R1表位扩展是原发性膜性肾病患者缓解率降低的独立预测因素。
研究设计与样本
- 前瞻性队列研究,纳入58例PLA2R1抗体阳性的原发性膜性肾病患者,随机分配至利妥昔单抗组(n=29)或仅抗蛋白尿治疗组(n=29)。
主要发现
- 基线表位扩展与PLA2R1抗体滴度强相关(P<0.001)。
- 调整年龄、性别、基线PLA2R1抗体水平和治疗分组后,基线表位扩展与第6个月缓解率降低相关(OR=0.16,95%CI 0.04-0.72,P=0.02)。
- 基线表位扩展与末次随访(中位23个月)缓解率降低相关(OR=0.14,95%CI 0.03-0.64,P=0.01)。
临床怎么用
- 建议在原发性膜性肾病患者决策早期治疗干预时考虑基线表位扩展情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phospholipase A2 receptor (PLA2R1) is the major autoantigen in primary membranous nephropathy. Several PLA2R1 epitopes have been characterized, and a retrospective study identified PLA2R1 epitope spreading as a potential indicator of poor prognosis. Here, we analyzed the predictive value of anti-PLA2R1 antibody (PLA2R1-Ab) titers and epitope spreading in a prospective cohort of 58 patients positive for PLA2R1-Ab randomly allocated to rituximab (n=29) or antiproteinuric therapy alone (n=29). At baseline, the epitope profile (CysR, CysRC1, CysRC7, or CysRC1C7) did not correlate with age, sex, time from diagnosis, proteinuria, or serum albumin, but epitope spreading strongly correlated with PLA2R1-Ab titer (P<0.001). Ten (58.8%) of the 17 patients who had epitope spreading at baseline and were treated with rituximab showed reversal of epitope spreading at month 6. In adjusted analysis, epitope spreading at baseline was associated with a decreased remission rate at month 6 (odds ratio, 0.16; 95% confidence interval, 0.04 to 0.72; P=0.02) and last follow-up (median, 23 months; odds ratio, 0.14; 95% confidence interval, 0.03 to 0.64; P=0.01), independently from age, sex, baseline PLA2R1-Ab level, and treatment group. We propose that epitope spreading at baseline be considered in the decision for early therapeutic intervention in patients with primary membranous nephropathy.
引用
- Seitz-Polski B, Debiec H, Rousseau A, et al. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. J Am Soc Nephrol. 2017. PMID: 29114041. doi:10.1681/ASN.2017070734
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。